Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended): A process for preparing a compound of Formula (I):



(I)

from a benzazepine-phenol of Formula (II):



(II),

wherein the benzazepine-phenol of Formula (II) is prepared by a process comprising converting a compound of Formula (III):



(III)

to a compound of Formula (IV):



(IV);

wherein:

R^P is H or a suitable phenol protecting group;

R^3 and R^4 are the same or different and are each independently H or a carboxylic acid ester protecting group;

R^2 is R^7, C_1-C_4 alkyl, C_1-C_4 haloalkyl, A-C_0-C_4 alkyl-, A-C_2-C_4 alkenyl-, A-C_2-C_4 alkynyl-, A-C_3-C_4 oxoalkenyl-, A-C_3-C_4 oxoalkynyl-, A-C_0-C_4 aminoalkyl-,

A-C_3-C_4 aminoalkenyl-, A-C_3-C_4 aminoalkynyl-, optionally substituted by any accessible combination of one or more of R^{10} or R^7;

A is H, C_3-C_6 cycloalkyl, Het or Ar;

R^7 is -COR^8, -$COCR'_2R^9$, -$C(S)R^8$, -$S(O)_mOR'$, -$S(O)_mNR'R''$, -PO(OR'), -$PO(OR')_2$, -NO_2, or tetrazolyl;

each R^8 independently is -OR', -NR'R", -$NR'SO_2R'$, -NR'OR', or -$OCR'_2CO(O)R'$;

R^9 is -OR', -CN, -$S(O)_rR'$, -$S(O)_mNR'_2$, -C(O)R', C(O)NR'_2, or -CO_2R';

R^{10} is H, halo, -OR^{11}, -CN, -$NR'R^{11}$, -NO_2, -CF_3, $CF_3S(O)_r$-, -CO_2R', -$CONR'_2$, A-C_0-C_6 alkyl-, A-C_1-C_6 oxoalkyl-, A-C_2-C_6 alkenyl-, A-C_2-C_6 alkynyl-, A- C_0-C_6 alkyloxy-, A-C_0-C_6 alkylamino- or A-C_0-C_6 alkyl-$S(O)_r$-;

R^{11} is R', -C(O)R', -$C(O)NR'_2$, -C(O)OR', -$S(O)_mR'$, or -$S(O)_mNR'_2$;

R^1 is


,

,

,

,

,

,

,

, or



;

W is $-(CHR^g)_a-U-(CHR^g)_b-$;

U is absent or CO, CR^g_2, $C(=CR^g_2)$, $S(O)_k$, O, NR^g, CR^gOR^g, $CR^g(OR^k)CR^g_2$, $CR^g_2CR^g(OR^k)$, $C(O)CR^g_2$, $CR^g_2C(O)$, $CONR^i$, NR^iCO, OC(O), C(O)O, C(S)O, OC(S), $C(S)NR^g$, $NR^gC(S)$, $S(O)_2NR^g$, $NR^gS(O)_2$ N=N, NR^gNR^g, $NR^gCR^g_2$, $CR^g_2NR^g$, CR^g_2O OCR^g_2, C≡C or CR^g=CR^g;

G is NR^e, S or O;

R^g is H, C_1-C_6 alkyl, Het-C_0-C_6 alkyl, C_3-C_7 cycloalkyl-C_0-C_6 alkyl or Ar-C_0-C_6 alkyl;

R^k is R^g, $-C(O)R^g$, or $-C(O)OR^f$;

R^i is H, C_1-C_6 alkyl, Het-C_0-C_6 alkyl, C_3-C_7 cycloalkyl-C_0-C_6 alkyl, Ar-C_0-C_6 alkyl, or C_1-C_6 alkyl substituted by one to three groups chosen from halogen, CN, NR^g_2, OR^g, SR^g, CO_2R^g, and $CON(R^g)_2$;

[[R^g]] $\underline{R^f}$ is H, C_1-C_6 alkyl or Ar-C_0-C_6 alkyl;

R^e is H, C_1-C_6 alkyl, Ar-C_0-C_6 alkyl, Het-C_0-C_6 alkyl, C_3-C_7 cycloalkyl-C_0-C_6 alkyl, or $(CH_2)_kCO_2R^g$;

R^b and R^c are independently selected from H, C_1-C_6 alkyl, Ar-C_0-C_6 alkyl, Het-C_0-C_6 alkyl, or C_3-C_6 cycloalkyl-C_0-C_6 alkyl, halogen, CF_3, OR^f, $S(O)_kR^f$, COR^f, NO_2, $N(R^f)_2$, $CO(NR^f)_2$, $CH_2N(R^f)_2$, or R^b and R^c are joined together to form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF_3, C_1-C_4 alkyl, OR^f, $S(O)_kR^f$, COR^f, CO_2R^f, OH, NO_2, $N(R^f)_2$, $CO(NR^f)_2$, and $CH_2N(R^f)_2$; or methylenedioxy;

Q^1, Q^2, Q^3 and Q^4 are independently N or C-R^y, provided that no more than one of Q^1, Q^2, Q^3 and Q^4 is N;

R' is H, C_1-C_6 alkyl, Ar-C_0-C_6 alkyl or C_3-C_6 cycloalkyl-C_0-C_6 alkyl;

R" is R', -C(O)R' or -C(O)OR';

R"' is H, C_1-C_6 alkyl, Ar-C_0-C_6 alkyl, Het-C_0-C_6 alkyl, or C_3-C_6 cycloalkyl-C_0-C_6 alkyl, halogen, CF_3, OR^f, $S(O)_kR^f$, COR^f, NO_2, $N(R^f)_2$, $CO(NR^f)_2$, $CH_2N(R^f)_2$;

R^y is H, halo, $-OR^g$, $-SR^g$, -CN, $-NR^gR^k$, $-NO_2$, $-CF_3$, $CF_3S(O)_r-$, $-CO_2R^g$, $-COR^g$ or $-CONR^g_2$, or C_1-C_6 alkyl optionally substituted by halo, $-OR^g$, $-SR^g$, -CN, $-NR^gR"$, $-NO_2$, $-CF_3$, $R'S(O)_r-$, $-CO_2R^g$, $-COR^g$ or $-CONR^g_2$;

a is 0, 1 or 2;

b is 0, 1 or 2;

k is 0, 1 or 2;

m is 1 or 2;

r is 0, 1 or 2;

s is 0, 1 or 2;

u is 0 or 1; and

v is 0 or 1;

or a pharmaceutically acceptable salt thereof.

2. (Previously presented): A process according to claim 1, comprising preparing a compound of Formula (I-S):



(I-S)

from a benzazepine-phenol of Formula (II-S):



(II-S),

wherein the benzazepine-phenol of Formula (II-S) is prepared by a process comprising converting a compound of Formula (III):



(III)

to a compound of Formula (IV-S):



(IV-S).

3. (Previously presented): A process according to claim 1, further comprising a process for preparing the compound of Formula (II) comprising the steps of:

1) treating a compound having Formula (a)



(a)

wherein R^P is H or a suitable phenol protecting group and X is halogen, $-OSO_2F$, or $-OSO_2CF_3$,

with a compound having the formula:



to form a compound of Formula (b)



(b);

2) converting the compound of Formula (b) to a compound of Formula (c);



(c)

wherein R^5 and $R^{5'}$ are C_1-C_4 alkyl or R^5 and $R^{5'}$, taken together with the atoms to which they are attached form a saturated 5- or 6-membered heterocyclic ring and Z and Z' are independently selected from O, NH or NCH_3;

3) converting the compound of Formula (c) to a compound of Formula (d):



(d);

4) converting the compound of Formula (d) to a compound of Formula (e)



(e);

5) converting the compound of Formula (e) to a compound of Formula (f)



(f); and

6) converting the compound of Formula (f) to a compound of Formula (II).

4. (Previously presented): A process according to claim 1, further comprising a process for preparing the compound of Formula (II) comprising the steps of:

1) converting 3-hydroxybenzaldehyde to a compound of Formula (aa)



(aa);

2) treating the compound of Formula (aa) with itaconic acid to form a compound of Formula (bb):



(bb);

3) converting the compound of Formula (bb) to a compound of Formula (cc)



(cc),

where R^5 and $R^{5'}$ are C_1-C_4 alkyl or R^5 and $R^{5'}$, taken together with the atoms to which they are attached form a saturated 5- or 6-membered heterocyclic ring;

4) converting the compound of Formula (cc) to a compound of Formula (dd)



(dd);

5) converting the compound of Formula (dd) to a compound of Formula (ee)



(ee); and

6) converting the compound of Formula (ee) to a compound of Formula (II).

5. (Previously presented): A process according to claim 2, further comprising a process for preparing the compound of Formula (II-S) comprising the steps of:

1) converting the compound having the formula:



;

wherein R^5 and $R^{5'}$ are C_1-C_4 alkyl or R^5 and $R^{5'}$, taken together with the atoms to which they are attached form a saturated 5- or 6-membered heterocyclic ring and Z and Z' are independently selected from O, NH or NCH_3, to a compound having the formula:



2) converting the compound formed in step 1) into a compound having the formula:



3) converting the compound formed in step 2) into the compound having the formula:



; and

4) converting the compound formed in step 3) into the compound of Formula (II-S).

6. (Previously presented): A process according to claim 2, further comprising a process for preparing the compound of Formula (II-S) comprising the steps of:

1) converting the compound having the formula:



wherein R^5 and $R^{5'}$ are C_1-C_4 alkyl or R^5 and $R^{5'}$, taken together with the atoms to which they are attached form a saturated 5- or 6-membered heterocyclic ring, into a compound having the formula:



2) converting the compound formed in step 1) into a compound having the formula:



; and

3) converting the compound formed in step 2) into the compound of Formula (II-S).

7. (Previously presented): A process according to claim 1, further comprising a process for preparing the compound of Formula (I) having the formula:



comprising the steps of:

1) converting 2-amino-6-methylpyridine into a compound having the formula:



,

wherein R^P is a suitable amino protecting group;

2) converting the compound formed in step 1) to a compound having the formula:



;

3) converting the compound formed in step 2) to a compound having the formula:



,

wherein R^6 is H or an alkyl carboxylic acid ester protecting group;

4) converting the compound formed in step 3) to a compound having the formula:



;

5) treating the compound formed in step 4) with a compound having the formula:



to form a compound having the formula:



; and

6) converting the compound formed in step 5) to the compound of Formula I.

8. (Previously presented): A process according to claim 1, further comprising a process for preparing the compound of Formula (I) having the formula:



comprising the steps of:

1) converting 2-amino-6-methylpyridine into a compound having the Formula:


;

2) converting the compound formed in step 1) to a compound having the formula:


;

3) converting the compound formed in step 2) to a compound having the formula:


;

4) converting the compound formed in step 3) to a compound having the formula:


;

5) treating the compound formed in step 4) with a compound having the formula:



to form a compound having the formula:



; and

6) converting the compound formed in step 5) to the compound of Formula (I).

9. (Previously presented): A process according to claim 1, further comprising a process for preparing the compound of Formula (I) having the formula:



comprising the steps of:

1) converting a compound having the formula:



wherein X is halogen or $-OSO_2CF_3$, to a compound having the formula:



;

2) converting the compound formed in step 1) into a compound having the formula:



,

wherein X' is halogen, $-OSO_2CH_3$, $-OSO_2CF_3$, $-OSO_2$(phenyl), or $-OSO_2$(p-tolyl);

3) treating the compound formed in step 2) with a compound having the formula:



to form a compound having the formula:



; and

4) converting the compound formed in step 3) into the compound of Formula (I).

10. (Previously presented): A process according to claim 1, further comprising a process for preparing the compound of Formula (I) having the formula:



comprising the steps of:

1) converting 2-chloropyrdine, N-oxide to a compound having the formula:



;

2) converting the compound formed in step 1) into a compound having the formula:



;

3) treating the compound formed in step 2) with a compound having the formula:



to form a compound having the formula:



; and

4) converting the compound formed in step 3) into the compound of Formula (I).

11. (Previously presented): A process according to claim 1, wherein R^3 is H, C_1-C_6 alkyl or phenyl-C_1-C_4 alkyl-, wherein the phenyl moiety is unsubstituted or substituted by one or more substituents selected from ortho and para substituents selected from chloro, bromo, nitro, methoxy and methyl and R^4 is H, C_1-C_6 alkyl or phenyl-C_1-C_4 alkyl-, wherein the phenyl moiety is unsubstituted or substituted by one or more substituents selected from ortho and para substituents selected from chloro, bromo, nitro, methoxy and methyl.

Claims 12-15 (Cancelled).

16. (Previously presented): A process according to claim 1, wherein R^4 is H or C_1-C_4 alkyl and R^3 is H or C_1-C_4 alkyl.

17. (Previously presented): A process according to claim 1, wherein R^4 is H and R^3 is methyl.

18. (Previously presented): A compound having the formula:



,

wherein:

R^P is H or a suitable phenol protecting group;

R^4 is H or a carboxylic acid ester protecting group;

R^5 and $R^{5'}$ are C_1-C_4 alkyl or R^5 and $R^{5'}$, taken together with the atoms to which they are attached form a saturated 5- or 6-membered heterocyclic ring and Z and Z' are independently selected from O, NH or NCH_3;

or a pharmaceutically acceptable salt or solvate thereof.

19. (Previously presented): A compound according to claim 18, wherein R^4 is H, C_1-C_6 alkyl or phenyl-C_1-C_4 alkyl-, wherein the phenyl moiety is unsubstituted or substituted by one or more substituents selected from ortho and para substituents selected from chloro, bromo, nitro, methoxy and methyl.

Claim 20 (Canceled).

21. (Previously presented) A compound according to claim 18, wherein R^4 is H, R^P is H, Z and Z' are both O, and R^5 and $R^{5'}$ are methyl.

22. (Previously presented): A compound having the formula:



wherein::

R^P is H or a suitable phenol protecting group;

R^3 is H or a carboxylic acid ester protecting group;

or a pharmaceutically acceptable salt or solvate thereof.

23. (Previously presented): A compound according to claim 22, wherein R^3 is H, C_1-C_6 alkyl or phenyl-C_1-C_4 alkyl-, wherein the phenyl moiety is unsubstituted or substituted by one or more substituents selected from ortho and para substituents selected from chloro, bromo, nitro, methoxy and methyl.

Claims 24-26 (Canceled).

27. (Previously presented): A compound according to claim 22, wherein R^P is H and R^3 is H or C_1-C_4 alkyl.

Claims 28-30 (Canceled).

31. (Currently amended): A compound:

~~8-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-1,2,4,5-tetrahydro-2-benzazepine-4-acetic acid,~~

~~S-(-)-8-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-1,2,4,5-tetrahydro-2-benzazepine-4-acetic acid,~~

~~2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-1H-2-benzazepine-4-acetic acid,~~

~~(S)-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-1H-2-benzazepine-4-acetic acid,~~

~~methyl-2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-(2,2,2-trifluoroethyl)-1H-2-benzazepine-4-acetate,~~

~~(S)-methyl-2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-(2,2,2-trifluoroethyl)-1H-2-benzazepine-4-acetate,~~

2-[(2-formyl-4-hydroxyphenyl)methylidene]succinic acid,

2-carboxyl-4-[(2-formyldimethylacetal-4-hydroxyphenyl)] butyric acid, bis(dicyclohexylamine) salt,

(S)-2-carboxyl-4-[(2-formyldimethylacetal-4-hydroxyphenyl)] butyric acid, bis(dicyclohexylamine) salt,

dimethyl 2-[(2-formyl-4-hydroxyphenyl)methyl]butanedioate, [[~~and~~]] or

dimethyl (2S)-2-[(2-formyl-4-hydroxyphenyl)methyl]butanedioate.

Claim 32 (Canceled).